CytRx
Corporation CYTR today announced compelling
preliminary data from its global Phase 2b soft tissue sarcoma trial
indicating that patients treated with aldoxorubicin had a significantly
higher OVERALL RESPONSE RATE (ORR) of 22% as compared to those
administered the widely used chemotherapeutic agent doxorubicin with an
ORR of 0%.
Additionally, aldoxorubicin compared with doxorubicin produced
statistically significant improvement in survival rates in animals with
a human model of glioblastoma (brain tumor), and showed an improved and
narrow distribution of aldoxorubicin within the human body in a
pharmacokinetics trial. Results from the glioblastoma trial and
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in